Amgen Presents

KRAS G12C Is Now Actionable in NSCLC!

KRAS mutations are the most common oncogenic drivers in non–small cell lung cancer (NSCLC) and nearly half are represented by the KRAS G12C variant.1 At 13% (or, 1 in 8 patients), KRAS G12C is one of the most prevalent mutations in non-squamous NSCLC.1,*

Join Amgen’s Dr. Greg Friberg, Vice President of Global Development at Amgen Oncology, for a webcast to learn more.

This program is intended for healthcare providers. If you have any questions, please visit Amgen's Medical Information website here

Register to watch
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

GregFriberg

Greg Friberg, MD

VICE PRESIDENT OF GLOBAL DEVELOPMENT, AMGEN ONCOLOGY

Greg received his A.B. degree in biochemistry from Middlebury College and M.D. from New York Medical College. He completed his residency training in Internal Medicine at Dartmouth-Hitchcock Medical Center and his fellowship training in Hematology and Oncology at The University of Chicago Hospitals. As part of his training, he graduated from the University of Chicago Health Sciences Department Clinical Research Training Program specializing in clinical trial design and analysis. He joined the faculty of the University of Chicago thereafter joining the Phase I, Gastrointestinal, and Gynecologic oncology teams where he served as the PI for multiple early phase clinical studies. He published multiple research papers and reviews, and he was an active member of ASCO, the CALGB, and the GOG.

Greg joined Amgen in 2006 as an Associate Medical Director in Oncology Early Development. He served as the team lead for multiple early and mid-stage programs, shepherding molecules through filings, into initial human studies, and onto later development. Greg took over as group leader in 2011 and served for 3 years as Head of Oncology Early Development and later for 4 months as Early Development Head (Oncology, Inflammation, Neuroscience, and General Medicine/Bone). Starting in 2014, Greg served as the interim Head for Hematology / Oncology. In 2016 he served as the Global Product General Manager (GPGM) for the early hematology BiTE portfolio.

In 2017 Greg assumed the role of Vice President and Head of Hematology / Oncology Global Development. In addition, in 2019 Greg assumed the responsibilities for the Bone franchise.

USA-510-80430

*Based on an analysis of NSCLC participants in the AACR GENIE version 8.0 dataset (n=14,485).1
AACR, American Association for Cancer Research; ASCO, American Society of Clinical Oncology; KRAS, Kirsten rat sarcoma viral oncogene homolog; NSCLC, non‒small cell lung cancer; PI, principal investigator.

Reference: 1. Data on File, Amgen [Analysis from AACR GENIE v8].